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EFFECT OF OCTREOTIDE ON GROWTH HORMONE
SECRETION IN PATIENTS WITH ACROMEGALY
Branka Vizner, Milan Vrkljan, Mladen Sekso, Maja BerkoviÊ, Josip ReπetiÊ and Miljenko Kalousek
Center for Clinical Neuroendocrinology and Pituitary Diseases, Sestre milosrdnice University Hospital, Zagreb, Croatia
SUMMARY ∑ A majority of growth hormone secreting pituitary adenomas respond well to soma-
tostatin and somatostatin analogues. The acute action of octreotide, a synthetic somatostatin ana-
logue, on growth hormone secretion was assessed in 42 patients with clinically and laboratory veri-
fied acromegaly. Octreotide was administered subcutaneously in a dose of 50 µg. Blood sampling
was performed at 1-hour intervals during 6 hours of testing. The mean basal values of growth hor-
mone (χ±SE) was 26.3±4.5 ng/ml (range 6.1-66.6 ng/ml), and of IGF-I 2940±171.7 IU/l (range
2350-4856 IU/l). Reduction in growth hormone values below 5 ng/ml was recorded in 31 (73.8%),
suppression by more than 50% in 5 (11.9%) and by more than 45% in 3 (7.1%) patients. Maximal
suppression was noticed in the first two hours of testing. In 3 (7.1%) patients, resistance to octreotide
with no change in growth hormone values was observed. In conclusion, octreotide reduces growth
hormone values in most acromegalic patients. A small proportion of acromegalic patients do not
respond well to octreotide, probably due to the lack of somatostatin receptors on tumor cells. We
consider the acute octreotide test as a very useful tool in triage of acromegalic patients eligible for
medicamentous treatment.
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Introduction
Growth hormone (GH) secreting pituitary tumors are
associated with elevated levels of GH and its target fac-
tor, insulin-like growth factor I (IGF-I). Most of them are
macroadenomas at the time of diagnosis, and patients
with these large tumors have a high rate of surgical fail-
ure and require adjunctive therapy to suppress GH secre-
tion1. External irradiation as a therapeutic modality is
associated with significant side effects, including hypopi-
tuitarism, which impair the long term benefit2.
In the mid-1980s, somatostatin and the somatostatin
analogue octreotide were first used to treat GH-cell ad-
enomas3. The response to octreotide is dependent on the
presence of somatostatin receptors in the tumor. Although
most tumors contain somatostatin receptors in densities
that are comparable to those in normal somatotrophs and
respond normally to somatostatin, 10% to 30% of GH-
secreting tumors have reduced numbers of somatostatin
receptors or express different subtypes of receptors (five
classes are known at present), and therefore exhibit dimin-
ished responses to pharmacotherapy4.
In order to predict long term responsiveness to octreo-
tide in patients with acromegaly, we used acute suppres-
sive effect of a single 50 µg injection of octreotide5.
Patients and Methods
The acute action of octreotide on GH secretion was
assessed in 42 patients (22 female and 20 male, mean age
48.1±2.4 years) with verified pituitary somatotrophinoma
and full-blown clinical picture of acromegaly. Serum IGF-
I, basal GH concentration (calculated from mean values
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during the 6-hour basal secretion test), and GH values on
oral glucose tolerance test (oGTT) with 100 g glucose
were determined6. GH values of less than 1 ng/ml after
glucose load were considered as appropriate suppression.
Computed tomography (CT) of the pituitary region was
performed on a Siemens Somatom with 2-mm cuts of the
sella. IGF-I and GH values were determined using IRMA
and classic RIA, respectively. The minimum detection
limit for IGF-I was 152 IU/l, and IRMA intra-assay pre-
cision on IGF-I determination was 4.5%. Theoretical sen-
sitivity of RIA, used to determine GH values, was 0.25
ng/ml, and intra-assay precision was 5.9%. Reference val-
ues of  IGF-I ranged between 600 and 2200 IU/l, and GH
upper limit was 5 ng/ml.
The acute octreotide test was performed with 50 µg
s.c. injection of octreotide. Blood samples were obtained
immediately before, and then at 1-hour intervals during
the 6-hour test duration. The results were expressed as
mean and standard error (χ±SE). All patients volunteered
in the study and were informed in detail on the purpose
of the test.
Results
The presence of a tumor mass of less than 10 mm in
diameter was confirmed by CT in 11 female patients, and
macroadenoma was diagnosed in 31 patients. The mean
Fig. 1. Growth hormone values in 42 acromegalic patients during octreotide suppression test
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basal GH value χ±SE) was 26.3±4.5 ng/ml (range 6.1-
66.6 ng/ml). The mean IGF-I value was 2940.2±171.7
IU/l (range 2350-4856 IU/l). None of our patients re-
sponded to oGTT with reduction in GH values.
Octreotide was used in the form of 50 µg s.c. injec-
tion. Blood samples were drawn at 1-hour intervals over
6-hour test duration. GH value reduction of ≤5 ng/ml was
observed in 31 (73.8%), suppression by more than 50%
in five (11.9%), and by >45% in three (7.1%) patients
(Table 1, Fig. 1). Resistance to octreotide with no change
in GH values was recorded in three (7.1%) patients.
Maximal suppression was observed during the first two
hours of the octreotide test (Fig. 2).
Table 1. Results of acute octreotide test in 42 acromegalic pa-
tients
Test result No. of patients % of patients
GH normalization 31 73.8
Suppression >50% 5 11.9
Suppression >45% 3 7.1
Octreotide resistance 3 7.1
GH=growth hormone
Discussion
Somatostatin analogues are amongst the most impor-
tant advances in endocrinology over the past 20 years.
They are indicated in patients with acromegaly in whom
there is a large macroadenoma not likely to be cured by
surgery, or in whom surgery was unsuccessful, contrain-
dicated, or refused. Somatostatin analogues can be used
either as primary pharmacotherapy for acromegaly or as
an adjunctive treatment in patients receiving irradiation,
or in those awaiting surgery who have severe symptoms
such as headache or episodes of sleep apnea7,8. Lombardi
et al. in a study including 557 acromegalic patients showed
that octreotide administration normalized IGF-I levels in
48.5% and shrank tumor size in 40.3% of patients. The
latter effect seems to favor the complete removal of the
somatotrophinoma at the surgery. Furthermore, preopera-
tive treatment with octreotide was shown to improve the
clinical status of the patients (especially headache, hyper-
hidrosis, and joint pain) and to reduce postoperative com-
plications9. Lamberts investigated octreotide therapy suc-
cess in 46 acromegalics and predicted biochemical ‘cure’
(defined by mean 24-hour GH normalization and serum
IGF-I normalization) in about half of the patients dur-
ing therapy with 300 µg octreotide daily. He also observed
tumor shrinkage in about 50% of patients, probably be-
cause of the drug-induced individual cell decrease rather
than cytotoxic or vascular effect of the drug10. Almost
identical results were obtained by Melmed, who reports
on GH normalization in 47% and IGF-I reduction to ref-
erence values in up to 70% of acromegalic patients1.
The discovery and use of octreotide really heralded a
new era for the pharmacological treatment of somatotrop-
hinomas, and new investigations are aimed at discovering
different somatostatin receptor subtypes, since it is known
that it exerts its action through receptor binding. To date,
5 receptor classes have been identified, and octreotide
probably binds to subtypes 2 and 5. Most tumors contain
receptors in amounts that resemble those of normal
somatotrophs11. However, 10% to 30% of tumors have
reduced numbers of receptors or express different recep-
tor subtypes and therefore exhibit a correspondingly de-
creased response5. Keeping in mind the cost of octreotide
and similar agents, efforts have been made to find a tool
to predict the patient’s response before embarking upon
this approach. We tested the effects of an acute s.c. octreo-
tide injection as a tool of long term responsiveness to so-
matostatin analogues. We achieved normalization in
73.8% and suppression by >50% in 11.9% of patients,
which was consistent with the results reported by Froh-
man5. Maximal suppression was achieved during the first
two hours of the test, then GH raised slightly almost rea-
ching the upper limit (5 ng/ml) and remained stable thro-
ughout the test duration. This GH dynamics differed from
that observed by Frohman. In his study, maximal sup-
pression of GH levels occurred at 2-4 hours, whereafter
it began to rise reaching the preinjection value.
The mean hourly GH level at 2-6 hours from octreo-
tide injection exhibited a high degree of correlation with
the 24-hour integrated GH level. It also correlated with
the plasma level of IGF-I, which is a useful marker of the
overall response.
Conclusion
Octreotide normalizes GH values in most acromega-
lic patients (73.8%). Maximal suppression is achieved dur-
ing the first two hours of acute octreotide suppression test.
However, some patients fail to respond to the action of
octreotide, probably because of the low number of soma-
tostatin receptors expressed on tumor cells or of different
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receptor subtypes present on cell membranes. We believe
that acute octreotide test is very useful for triage of ac-
romegalic patients eligible for medicamentous treatment
with somatostatin analogues.
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Saæetak
UTJECAJ OKTREOTIDA NA LU»ENJE HORMONA RASTA U BOLESNIKA S AKROMEGALIJOM
B. Vizner, M. Vrkljan, M. Sekso, M. BerkoviÊ, J. ReπetiÊ i M. Kalousek
VeÊina adenoma hipofize koji luËe hormon rasta zadræe osjetljivost na somatostatin i njegove analoge. Ispitivano je akutno
djelovanje oktreotida, sintetskog oktapeptidnog analoga somatostatina, na razinu hormona rasta u 42 bolesnika s kliniËki i
laboratorijski potvrenom akromegalijom. Oktreotid je primijenjen supkutano u dozi od 50 µg. Uzorci krvi za odreivanje
hormona rasta uzimani su svakog sata u razdoblju od πest sati. ProsjeËna bazalna vrijednost hormona rasta bila je 26,3±4,5
χ±SE) ng/ml (raspon 6,1-66,6 ng/ml), a IGF-I 2940,2±171,7 IJ/l (raspon 2350-4856 IJ/l). Nakon primjene oktreotida razina
hormona rasta u serumu snizila se na normalne vrijednosti (<5 ng/ml) u 31 (73,8%) bolesnika, u 5 (11,9%) bolesnika nastupilo
je sniæenje za viπe od 50%, a u 3 (7,1%) za viπe od 45%. Maksimalno je sniæenje u ovih bolesnika uslijedilo jedan do dva sata
nakon poËetka testa. Troje (7,1%) bolesnika pokazalo je rezistenciju na oktreotid. Njihove vrijednosti hormona rasta ostale su
gotovo jednake onima u bazalnim uvjetima. ZakljuËeno je da oktreotid normalizira razinu hormona rasta u veÊine akromegaliËnih
bolesnika, meutim, u nekih se ne postiæe zadovoljavajuÊi odgovor, vjerojatno zbog malog broja somatostatinskih receptora na
membrani tumorskih stanica. Smatramo da je akutni test s oktreotidom koristan u odabiru akromegaliËnih bolesnika za
konzervativno lijeËenje analozima somatostatina.
KljuËne rijeËi: Akromegalija, medikamentno lijeËenje; Oktreotid, terapijska primjena; Oktreotid, farmakologija
